NR507 / NR 507 ADVANCED PATHOPHYSIOLOGY
Enhanced Midterm Study Guide — Original Exam-Focused Q&A; Edition
Purpose: A comprehensive, original study resource built around the publicly visible topic structure of the referenced
NR507 Stuvia listing. It is designed for active recall, mechanism-based reasoning, and graduate-level clinical application.
Important: This is not a reproduction of locked or paid source text, nor does it claim to contain actual or leaked examination
questions. The questions and explanations below are newly written practice material.
How to use: Cover the answer, explain the mechanism aloud, then check the rationale. For vignette questions, identify
the organ system, mechanism, expected finding, and best explanation before looking at the answer.
NR507 Advanced Pathophysiology — Enhanced Midterm Study Guide | Page 1
,1. IMMUNOLOGICAL PATHOLOGIES — HYPERSENSITIVITY &
AUTOIMMUNITY
Q: What is hypersensitivity?
Answer: Hypersensitivity is an exaggerated or inappropriate immune response that produces tissue injury rather than
useful protection. The classic framework divides reactions into Types I–IV. A high-yield distinction is that Types I–III are
primarily antibody-associated, whereas Type IV is T-cell mediated.
Q: What is Type I hypersensitivity?
Answer: Type I is an immediate, IgE-mediated reaction. Initial exposure promotes Th2 signaling, B-cell class switching to
IgE, and binding of IgE to mast cells and basophils. On re-exposure, allergen cross-linking triggers degranulation.
Histamine increases vascular permeability and contributes to vasodilation; leukotrienes promote bronchoconstriction and
mucus production.
Q: What is the key emergency associated with Type I hypersensitivity?
Answer: Anaphylaxis. The patient may develop hypotension, airway edema, wheezing, urticaria, gastrointestinal
symptoms, and cardiovascular collapse. The priority medication for anaphylaxis is intramuscular epinephrine because it
counteracts bronchoconstriction, mucosal edema, and vasodilation.
Q: How do antihistamines fit into Type I reactions?
Answer: Antihistamines primarily block histamine H1 receptors and can reduce itching, sneezing, urticaria, and some
vasodilation-related symptoms. They do not replace epinephrine in anaphylaxis.
Q: What is Type II hypersensitivity?
Answer: Type II is antibody-mediated injury or altered cellular function. IgG or IgM binds antigens associated with cell
surfaces or extracellular matrix. Complement activation, opsonization, antibody-dependent cellular cytotoxicity, or receptor
stimulation/blockade may result.
Q: Give clinically useful Type II examples.
Answer: ABO transfusion reactions illustrate antibody-mediated destruction of incompatible erythrocytes. Graves disease
illustrates antibody-mediated receptor stimulation, while myasthenia gravis illustrates antibody-mediated interference with
receptor function.
Q: What is Type III hypersensitivity?
Answer: Type III results from immune-complex formation. Antigen-antibody complexes circulate and deposit in tissues,
activating complement and recruiting inflammatory cells. The resulting inflammation can damage vessels, kidneys, joints,
and other tissues.
Q: How does systemic lupus erythematosus fit the hypersensitivity framework?
Answer: SLE has prominent immune-complex mechanisms and autoantibody production. Clinical manifestations can
involve skin, joints, kidneys, blood cells, nervous tissue, and serosal surfaces. Anti-nuclear antibodies are an important
laboratory clue, but diagnosis depends on the complete clinical and laboratory picture.
Q: What is Type IV hypersensitivity?
Answer: Type IV is a delayed, T-cell-mediated response and does not depend on antibody-antigen complexes. Sensitized
T cells release cytokines and/or directly injure target cells. Contact dermatitis, such as a reaction to poison ivy, is a classic
example.
Q: How can Type I and Type IV skin reactions be distinguished?
NR507 Advanced Pathophysiology — Enhanced Midterm Study Guide | Page 2
, Answer: Type I reactions are rapid and often involve widespread atopic manifestations. Type IV contact dermatitis is
delayed and typically localized to the area exposed to the offending substance. Timing plus distribution are powerful exam
clues.
Q: What is alloimmunity?
Answer: Alloimmunity, or isoimmunity, occurs when an individual's immune system reacts against antigens from another
genetically different member of the same species. Examples include transplant rejection, transfusion reactions, and
maternal immune responses against fetal antigens.
Q: What is a primary immunodeficiency?
Answer: A primary immunodeficiency is generally congenital and commonly reflects an inherited genetic defect affecting
immune development or function. Severe or recurrent infections, unusual organisms, poor growth, or persistent infections
can be clues.
Q: What is a secondary immunodeficiency?
Answer: A secondary immunodeficiency is acquired. Causes include malignancy, certain infections, immunosuppressive
therapies, nutritional deficiency, and physiologic aging. It is generally more common than primary immunodeficiency.
Q: What is the most important clinical clue to immunodeficiency?
Answer: Recurrent, severe, persistent, or unusually difficult-to-treat infections. The pattern can help identify which immune
component is impaired.
Exam focus: When a question asks for a mechanism, state the initiating event → physiologic change → clinical consequence.
This chain is usually more defensible than memorizing isolated facts.
NR507 Advanced Pathophysiology — Enhanced Midterm Study Guide | Page 3
Enhanced Midterm Study Guide — Original Exam-Focused Q&A; Edition
Purpose: A comprehensive, original study resource built around the publicly visible topic structure of the referenced
NR507 Stuvia listing. It is designed for active recall, mechanism-based reasoning, and graduate-level clinical application.
Important: This is not a reproduction of locked or paid source text, nor does it claim to contain actual or leaked examination
questions. The questions and explanations below are newly written practice material.
How to use: Cover the answer, explain the mechanism aloud, then check the rationale. For vignette questions, identify
the organ system, mechanism, expected finding, and best explanation before looking at the answer.
NR507 Advanced Pathophysiology — Enhanced Midterm Study Guide | Page 1
,1. IMMUNOLOGICAL PATHOLOGIES — HYPERSENSITIVITY &
AUTOIMMUNITY
Q: What is hypersensitivity?
Answer: Hypersensitivity is an exaggerated or inappropriate immune response that produces tissue injury rather than
useful protection. The classic framework divides reactions into Types I–IV. A high-yield distinction is that Types I–III are
primarily antibody-associated, whereas Type IV is T-cell mediated.
Q: What is Type I hypersensitivity?
Answer: Type I is an immediate, IgE-mediated reaction. Initial exposure promotes Th2 signaling, B-cell class switching to
IgE, and binding of IgE to mast cells and basophils. On re-exposure, allergen cross-linking triggers degranulation.
Histamine increases vascular permeability and contributes to vasodilation; leukotrienes promote bronchoconstriction and
mucus production.
Q: What is the key emergency associated with Type I hypersensitivity?
Answer: Anaphylaxis. The patient may develop hypotension, airway edema, wheezing, urticaria, gastrointestinal
symptoms, and cardiovascular collapse. The priority medication for anaphylaxis is intramuscular epinephrine because it
counteracts bronchoconstriction, mucosal edema, and vasodilation.
Q: How do antihistamines fit into Type I reactions?
Answer: Antihistamines primarily block histamine H1 receptors and can reduce itching, sneezing, urticaria, and some
vasodilation-related symptoms. They do not replace epinephrine in anaphylaxis.
Q: What is Type II hypersensitivity?
Answer: Type II is antibody-mediated injury or altered cellular function. IgG or IgM binds antigens associated with cell
surfaces or extracellular matrix. Complement activation, opsonization, antibody-dependent cellular cytotoxicity, or receptor
stimulation/blockade may result.
Q: Give clinically useful Type II examples.
Answer: ABO transfusion reactions illustrate antibody-mediated destruction of incompatible erythrocytes. Graves disease
illustrates antibody-mediated receptor stimulation, while myasthenia gravis illustrates antibody-mediated interference with
receptor function.
Q: What is Type III hypersensitivity?
Answer: Type III results from immune-complex formation. Antigen-antibody complexes circulate and deposit in tissues,
activating complement and recruiting inflammatory cells. The resulting inflammation can damage vessels, kidneys, joints,
and other tissues.
Q: How does systemic lupus erythematosus fit the hypersensitivity framework?
Answer: SLE has prominent immune-complex mechanisms and autoantibody production. Clinical manifestations can
involve skin, joints, kidneys, blood cells, nervous tissue, and serosal surfaces. Anti-nuclear antibodies are an important
laboratory clue, but diagnosis depends on the complete clinical and laboratory picture.
Q: What is Type IV hypersensitivity?
Answer: Type IV is a delayed, T-cell-mediated response and does not depend on antibody-antigen complexes. Sensitized
T cells release cytokines and/or directly injure target cells. Contact dermatitis, such as a reaction to poison ivy, is a classic
example.
Q: How can Type I and Type IV skin reactions be distinguished?
NR507 Advanced Pathophysiology — Enhanced Midterm Study Guide | Page 2
, Answer: Type I reactions are rapid and often involve widespread atopic manifestations. Type IV contact dermatitis is
delayed and typically localized to the area exposed to the offending substance. Timing plus distribution are powerful exam
clues.
Q: What is alloimmunity?
Answer: Alloimmunity, or isoimmunity, occurs when an individual's immune system reacts against antigens from another
genetically different member of the same species. Examples include transplant rejection, transfusion reactions, and
maternal immune responses against fetal antigens.
Q: What is a primary immunodeficiency?
Answer: A primary immunodeficiency is generally congenital and commonly reflects an inherited genetic defect affecting
immune development or function. Severe or recurrent infections, unusual organisms, poor growth, or persistent infections
can be clues.
Q: What is a secondary immunodeficiency?
Answer: A secondary immunodeficiency is acquired. Causes include malignancy, certain infections, immunosuppressive
therapies, nutritional deficiency, and physiologic aging. It is generally more common than primary immunodeficiency.
Q: What is the most important clinical clue to immunodeficiency?
Answer: Recurrent, severe, persistent, or unusually difficult-to-treat infections. The pattern can help identify which immune
component is impaired.
Exam focus: When a question asks for a mechanism, state the initiating event → physiologic change → clinical consequence.
This chain is usually more defensible than memorizing isolated facts.
NR507 Advanced Pathophysiology — Enhanced Midterm Study Guide | Page 3
